ZSCAN20 and hepatocellular carcinoma: We found that in enriched regulatory T cell cohorts, high expression of ZSCAN20 led to poor prognosis in HCC patients, but there was no significant association between low/high ZSCAN20 expression and HCC patient prognosis in decreased Regulatory T-cells cohorts (Figure 11A).